The management of esophageal cancer has been evolving over the past 30 years. In the United States, multimodality treatment combining chemotherapy and radiotherapy (RT) prior to surgical resection has come to be accep...The management of esophageal cancer has been evolving over the past 30 years. In the United States, multimodality treatment combining chemotherapy and radiotherapy (RT) prior to surgical resection has come to be accepted by many as the standard of care, although debate about its overall effect on survival still exists, and rightfully so. Despite recent improvements in detection and treatment, the overall survival of patients with esophageal cancer remains lower than most solid tumors, which highlights why further advances are so desperately needed. The aim of this article is to provide a complete review of the history of esophageal cancer treatment with the addition of chemotherapy, RT, and more recently, targeted agents to the surgical management of resectable disease.展开更多
食管小细胞癌(primary esophageal small cell carcinoma,PESCC)是一种恶性程度高、易远处转移、预后极差的罕见疾病,近年来,国内外食管小细胞癌的发病率呈明显上升趋势。食管小细胞癌是一种最常见的消化道小细胞癌,但其生物学行为、治...食管小细胞癌(primary esophageal small cell carcinoma,PESCC)是一种恶性程度高、易远处转移、预后极差的罕见疾病,近年来,国内外食管小细胞癌的发病率呈明显上升趋势。食管小细胞癌是一种最常见的消化道小细胞癌,但其生物学行为、治疗模式及预后均不同于食管鳞癌,国内外尚无关于PESCC的前瞻性随机对照研究。目前临床中对于其组织来源、诊断方式、治疗模式及预后因素尚未形成共识。为加深对PESCC的理解和更好地解决临床问题,本文就近年来食管小细胞癌的相关诊疗进展及不同见解作一综述。展开更多
文摘The management of esophageal cancer has been evolving over the past 30 years. In the United States, multimodality treatment combining chemotherapy and radiotherapy (RT) prior to surgical resection has come to be accepted by many as the standard of care, although debate about its overall effect on survival still exists, and rightfully so. Despite recent improvements in detection and treatment, the overall survival of patients with esophageal cancer remains lower than most solid tumors, which highlights why further advances are so desperately needed. The aim of this article is to provide a complete review of the history of esophageal cancer treatment with the addition of chemotherapy, RT, and more recently, targeted agents to the surgical management of resectable disease.
文摘食管小细胞癌(primary esophageal small cell carcinoma,PESCC)是一种恶性程度高、易远处转移、预后极差的罕见疾病,近年来,国内外食管小细胞癌的发病率呈明显上升趋势。食管小细胞癌是一种最常见的消化道小细胞癌,但其生物学行为、治疗模式及预后均不同于食管鳞癌,国内外尚无关于PESCC的前瞻性随机对照研究。目前临床中对于其组织来源、诊断方式、治疗模式及预后因素尚未形成共识。为加深对PESCC的理解和更好地解决临床问题,本文就近年来食管小细胞癌的相关诊疗进展及不同见解作一综述。
